You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
北大醫藥(000788.SZ)簽訂技術轉讓合同 擬取得莫西沙星相關無形資產組
格隆匯 04-17 17:53

格隆匯4月17日丨北大醫藥(000788.SZ)公佈,公司擬與方正醫藥研究院有限公司(以下簡稱“方正醫藥研究院”)簽署《技術轉讓(專利實施許可)合同》。方正醫藥研究院擬以排他方式將“一種鹽酸莫西沙星及其對映異構體的分離測定方法”、“鹽酸莫西沙星中酒石酸殘留量檢測方法”和“鹽酸莫西沙星中L-(+)-酒石酸的檢測方法”的專利權及鹽酸莫西沙星原料、注射液、氯化鈉注射液研究資料(以下簡稱“莫西沙星相關無形資產組”)許可給公司,許可期限為2020年4月17日至2034年6月19日。

若公司在2021年12月31日前順利獲得莫西沙星氯化鈉注射液藥品註冊批件,則許可實施使用費為2350萬元(含税);若公司在2021年12月31日前未能獲得莫西沙星氯化鈉注射液藥品註冊批件,則許可實施使用費為2090萬元(含税)。

莫西沙星相關無形資產組用於生產鹽酸莫西沙星原料藥、鹽酸莫西沙星注射液、鹽酸莫西沙星氯化鈉注射液。公司已取得鹽酸莫西沙星注射液的藥品註冊批件,批准文號為“國藥準字H20193431”;截止目前,鹽酸莫西沙星氯化鈉注射液藥品註冊批件正在申請中。

莫西沙星相關無形資產組終端產品為鹽酸莫西沙星注射液、鹽酸莫西沙星氯化鈉注射液,是最新一代(第四代)喹諾酮類廣譜抗菌藥,治療患有上呼吸道和下呼吸道感染的成人(≥18歲)。如急性細菌性鼻竇炎、慢性支氣管炎急性發作、社區獲得性肺炎、以及複雜和非複雜性皮膚和軟組織感染、複雜腹膜內感染。

莫西沙星為第四代喹諾酮類廣譜抗菌藥,具有抗菌譜廣、抗菌性強、半衰期長、在體內活性強、不良反應少、不易產生耐藥並對常見耐藥菌有效、安全性高等優點,其抗菌譜覆蓋全部呼吸道主要致病菌,是呼吸科常用藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account